Ataraxis Real-World Clinical Outcomes Registry Linking AI-Based Pathology Scores to Patient Outcomes

The ARC Registry is a large-scale, multi-site, prospective, observational registry. All patients with a solid tumor malignancy who receive Ataraxis testing as part of routine clinical care are eligible for enrollment, which will link Ataraxis test results with short- and long-term patient outcomes to evaluate the real-world performance and clinical utility of Ataraxis tests. The ARC Registry utilizes an adaptable design, where additional Sponsor-led analyses and investigator-initiated ancillary studies can be added after the initial study is opened.

Inclusion Criteria: * Aged 18 years or older at the time of consent. * Diagnosis of a solid tumor malignancy, confirmed histologically or cytologically. * Patient is undergoing Ataraxis testing as part of their routine clinical care. * Availability of a pathology specimen. * Willing and able to provide written informed consent. Exclusion Criteria: * Unable or unwilling to provide informed consent. * Patient for whom an Ataraxis test result was not successfully generated (e.g., due to sample quality, technical failure, or any reason resulting in a non-reportable result).